Company:  INSULET CORP (PODD)
Form Type:  10-K
Filing Date:  2/24/2021 
CIK:  0001145197 
Address:  100 NAGOG PARK 
City, State, Zip:  ACTON, Massachusetts 01720 
Telephone:  978-600-7000 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$287.13  
Change: 
2.57 (0.90%)  
Trade Time: 
Apr 09  
Market Cap: 
$18.97B
Trade PODD now with 

© 2021  
Description of Business
Insulet Corporation ("we" or the "Company") is primarily engaged in the development, manufacture and sale of its proprietary Omnipod® System, a continuous insulin delivery system for people with insulin-dependent diabetes, which we have been selling since 2005. The Omnipod System includes: the Omnipod Insulin Management System ("Omnipod") and the Omnipod DASHTM Insulin Management System ("Omnipod DASH" or "DASH"), our digital mobile Omnipod platform. In addition to the diabetes market space, we have partnered with pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across other therapeutic areas. Most of our drug delivery revenue consists of sales of pods to Amgen for use in the Neulasta® Onpro® kit, a delivery system for Amgen's white blood cell booster to help reduce the risk of infection after intense chemotherapy.
Register and access this filing in:     
  FORM 10-K
    PART I
      Item 1. Business
    Item 1A. Risk Factors
    PART II
      Item 5. Market for Registrant's Common Equity, Related ...
      Item 7. Management's Discussion and Analysis of Financial ...
        Results of Operations
          CASH FLOW
          BALANCE SHEET
        Report of Independent Registered Public Accounting Firm
        BALANCE SHEET
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        CASH FLOW
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
    VALUATION AND QUALIFYING ACCOUNTS
    PART II
      Item 9. Changes in and Disagreements With Accountants On ...
      Item 9A. Controls and Procedures
    PART III
      Item 10. Directors, Executive Officers and Corporate Governance
      Item 12. Security Ownership of Certain Beneficial Owners and ...
    PART IV
      Item 15. Exhibits, Financial Statement Schedules
    SIGNATURES
  EXHIBIT 10.56
  EXHIBIT 10.57
  EXHIBIT 21.1
    SUBSIDIARIES
  EXHIBIT 23.1
    Consent of Independent Registered Public Accounting Firm
  EXHIBIT 31.1
    CERTIFICATION
  EXHIBIT 31.2
    CERTIFICATION
  EXHIBIT 32.1
    CERTIFICATION PURSUANT TO